Development of a novel oral suspension formulation of a candidate API for administration to paediatric patients
Development of a novel oral suspension formulation of a candidate API for administration to paediatric patients.
Peer Reviewed Publication
Controlled synthesis of SPION@SiO2 nanoparticles using design of experiments
Controlled synthesis of SPION@SiO2 nanoparticles using design of experiments.
Streamlining the Delivery of 14C Human ADME Data: An ADME Q&A Roundtable
Experts from Quotient Sciences and The Netherlands Organization for Applied Scientific Research (TNO) discuss streamlining human ADME studies.
AAPS 2022 Poster: Kilo Scale Synthesis in Daisy Chained Flow Reactors
Quotient Sciences AAPS 2022 Poster, "Kilo Scale Synthesis in Daisy Chained Flow Reactors." (2R, 6R) hydroxynorketamine is a pharmaceutical undergoing trials as an antidepressant. An atom efficient synthesis route with norketamine as an intermediate is known. A low throughput flow synthesis route to norketamine had previously been developed, 2 however a manufacturing scale method was required. The objective of this study is to conduct the entire synthesis of norketamine from 2 chlorophenylcyclopentyl ketone in daisy chained reactors, built mainly from readily available parts at a throughput of > 1 kg/day.
AAPS 2022 Poster: Formulation and Taste Assessments in First in Human Studies
Quotient Sciences AAPS 2022 Poster, "Formulation and Taste Assessments in First in Human Studies"
Quotient Sciences Aseptic Development & Manufacturing Capabilities Info Sheet
Quotient Sciences has expertise in developing, manufacturing, testing, releasing, and supplying a range of formulations (IV, SC, and IM administration) for a variety of clinical study types, including first-in-human (FIH) healthy volunteer studies assessing safety, tolerability, and pharmacokinetics (PK), as well as radiolabeled formulations for human absorption, distribution, metabolism, and excretion (ADME) studies.
Quotient Sciences' Collaboration with Charles River
Integrated programs that bridge molecules from early discovery to proof of concept (POC) and beyond.
A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers.
"A Phase 1, Randomized, Double-Blind, Placebo Controlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers." The poster was presented at the Pharmacology 2022 conference and was co-authored with our customer, Galmed Pharmaceuticals
BPS 2022 Poster - A Phase 1 Randomized PK Study of Amilo-5MER
A Phase 1, Randomized, Double-Blind, PlaceboControlled, First-in-Human Study to Assess Safety, Tolerability & Pharmacokinetics (PK) of Amilo-5MER in Healthy Volunteers
Assessment of the Contribution of CYP2D6 to the Elimination of Idalopirdine as well as the Absolute Bioavailability Following Multiple Oral Dosing
This study assessed the contribution of CYP2D6 to the metabolization of idalopirdine by comparing pharmacokinetics in CYP2D6 extensive metabolizers (EM) and poor metabolizers (PM) following multiple oral dosing. Comparison of pharmacokinetic (PK) parameters in PMs and EMs may substitute for an interaction study of the effect of CYP2D6 inhibition
Peptide Development Strategies
Peptide drug products continue to gain popularity in the pharmaceutical industry due to their high selectivity, high potency, and good safety profile. However, formulating peptides can present many challenges for drug developers because of their unique physicochemical properties.
Applications of Lipid-based Formulations and the Benefits of Integrating Manufacturing and Clinical Testing in Formulation Selection
The purpose of this study is to analyze pharmaceutical and clinical data from multiple development programs to understand the drivers and outcomes of selecting and dosing different lipid formulations.